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Abstract: Perioperative ischemic complications not directly related to surgery require special attention
in patients with moyamoya disease; positron emission tomography (H(2) 15O-PET) and single-photon
emission computed tomography have been considered indispensable for evaluating pre- and postsurgical
cerebral hemodynamics. The clinical records of 14 patients with moyamoya disease who underwent 26
extracranial-intracranial bypass operations were reviewed with special reference to perisurgical compli-
cations. One patient developed multiple postoperative ischemic infarctions and died of ischemic brain
edema. The history of this patient with prolonged acidosis is analyzed, and the role of metabolic changes
induced by H(2) 15O-PET with acetazolamide challenge is reviewed. Seven (77.8%) of nine patients oper-
ated on within 48 hours after H(2) 15O-PET with acetazolamide (group 1) developed metabolic acidosis,
whereas only three (17.6%) of 17 patients operated on >48 hours (group 2) after the examination had
intraoperative pH of <7.35. In group 1, the mean intraoperative pH was 7.328, which was significantly
lower than the mean pH of 7.393 (P <.0001) in group 2. After H(2) 15O-PET with acetazolamide chal-
lenge, patients must be carefully observed concerning acidosis and volume state. We recommend at least
48 hours between examination and surgery for patients with moyamoya disease so that their conditions
can stabilize. Furthermore, special care should be taken to avoid additional perioperative risk factors
such as hypotension, hypocapnia, hypercapnia, and hypovolemia.
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The occurrence of perioperative ischemic complications not directly related to 
surgery requires special attention in patients with Moyamoya disease. H215O-PET 
(positron emission tomography) and SPECT (single photon emission computed 
tomography) examinations have been considered to be indispensable for evaluating 
pre- and postsurgical cerebral hemodynamics. The clinical records of 14 patients with 
Moyamoya disease and 26 extracranial-intracranial (EC-IC) bypass operations were 
reviewed with special reference to perisurgical complications. One patient developed 
multiple postoperative ischemic infarctions and died of ischemic brain edema. The 
history of this patient with prolonged acidosis is analyzed and the role of metabolic 
changes induced by H215O-PET examination with acetazolamide challenge is 
focused. Seven of nine patients (77.8%) operated within 48 hours after the H215O-
PET examination with acetazolamide (group one) developed metabolic acidosis 
whereas only three of 17 patients (17.6%) operated later than 48 hours (group two) 
after the examination showed intraoperative pH values below 7.35. In group one 
intraoperative pHmean was 7.328, which was significantly lower than pHmean 7.393 
(p<0.0001) of group two. Patients after H215O-PET examinations with acetazolamide 
challenge have to be carefully observed concerning acidosis and volume state. Time 
intervals of at least more than 48 hours between the examination and surgery are 
considered to be recommendable from our data to perform surgery in a stable 
condition of the patients with Moyamoya disease. Furthermore, special care should 
be taken to avoid additional perioperative risk factors such as hypotension, 













Moyamoya disease is a unique cerebrovascular disease with a much higher 
incidence in Japanese and other Asians than in Caucasians (1,2). It is characterized 
by a bilateral progressive cerebrovascular occlusion of the terminal portion of the 
internal carotid artery with a spontaneously developed collateral network, the so-
called Moyamoya vessels (1). The occurrence of these typical findings in association 
with other diseases is called Moyamoya syndrome (1). Moyamoya disease is 
subdivided into a juvenile and an adult type. The typical clinical manifestations are 
cerebral ischemia and intracerebral hemorrhage (1). Transient ischemic attacks 
(TIAs) and permanent ischemia are the most frequent manifestations in Europe (3). 
Since the late seventies cerebrovascular reconstruction surgery is successfully 
performed to treat ischemic symptoms in Moyamoya disease. Nevertheless the 
occurrence of perioperative ischemic complications not directly related to surgical 
technique is a serious problem and requires special attention (4,5,6,7,8,9). So far 
literature dealing with aspects of perioperative treatment in patients with Moyamoya 
disease is sparse. We report on a patient with Moyamoya disease who showed 
metabolic acidosis after H215O-PET (positron emission tomography) examination 
using acetazolamide and severe postoperative ischemic complications. Based on the 





acetazolamide is discussed, reviewing our experience in perioperative treatment of 
14 patients with Moyamoya disease or syndrome with 26 operations with 





The 36 years old female patient, presented with right sided hemiparesis, recovered 
completely within seven days. The preoperative MRI showed subacute infarctions in 
the left frontal and fronto-parietal region (fig. 1).  Angiography presented the typical 
Moyamoya disease pattern (fig. 2 and 3). There was no history of seizures. After an 
interval of three weeks without any symptoms, the patient underwent 2 bypasses 
(frontal branch of STA- prerolandic branch of MCA, parietal branch of STA- angular 
artery, branch of MCA). H215O-PET examination with acetazolamide challenge was 
performed 13 hours before the operation (fig. 4). Anesthesia was induced with 
propofol 90 mg i.v., followed by continuous infusion of propofol 300mg/h and fentanyl 
300 ug/h for the first three hours followed by remifentanyl 700ug/h. No volatile 
anesthetics were used. During the operation and postoperatively there were no signs 
of hypotension (mean arterial pressure (MAP) between 80 and 110 mmHg) or 
hypovolemia (central venous pressure (CVP) between 5 to 8 mmHg, normal serum 
lactate). Body temperature, obtained from the ear, decreased from 36.8 °C to 35.6°C 
during the operation and increased to a maximal value of 38.0 °C postoperatively. 
Hematocrit preoperatively was 34% and decreased to a minimal value of 30% 
postoperatively. First blood gas analysis during the operation showed an arterial pH 





hyperventilated with a PaCO2 of 3.7 kPa. Artificial ventilation after 15 minutes was 
adapted and PaCO2 at the end of the operation was 4.7 kPa. 50ml of Na-bicarbonate 
8.4% were given during the operation and at the end of the operation pH was 7.39, 
HCO3- 21.0 mmol/l and BE -2.6. Immediately after the operation the patient woke up 
without any neurological deficit. First blood gas analysis in the neurosurgical 
intensive care unit showed an arterial pH of 7.47, HCO3-- of 20.1 mmol/l, BE of --4.2 
and PaCO2 of 4.7 kPa during spontaneous ventilation and Serum-Na+ of 143 mmol/l.  
During the early postoperative period MAP ranged between 90 and 110 mmHg, 
hematocrit was 30%, body temperature was 36.8 °C, and urinary output ranged 
between 60 to 120 ml/hour. Six hours after the operation the patient deteriorated with 
generalized seizures. Arterial blood gas analysis taken 5 minutes before the event 
showed that pH decreased to 7.35, HCO3-- to 18.2 mmol/l, BE to --5.2 and a PaCO2 
to 4.1 kPa. Serum-Na+ was stable with 141 mmol/l. Immediate emergency 
resuscitation with induction of anesthesia (etomidate 0.3 mg/kg intravenously, 
combined with rocuroniumbromid 0.8 mg/kg and thiopental 5 mg/kg), endotracheal 
intubation and cardiovascular stabilization was performed. Arterial blood gas values 
normalized after 50ml Na-bicarbonate 8.4% intravenously. An emergency CT scan 
was carried out and showed multiple ischemias in the right MCA territory. Duplex 
sonography showed leftsided EC-IC bypass to be patent. No signs of cerebral 
vasospasm (mean blood flow velocities from middle, anterior and posterior cerebral 
arteries below 100 cm/sec) were documented. Assuming a critical diminished 
perfusion over the right hemisphere emergency EC-IC bypass (parietal branch of 
STA - angular artery, branch of MCA + frontal branch of STA - middle internal frontal 
branch of ACA) on the right side was performed without complications. At the end of 





inserted. Because of increasing ICP values over 20 mmHg the patient remained 
intubated, sedated  (fentanyl infusion 5 ug/kg/h and midazolam 0.4 mg/kg/h) and was 
treated with thiopental coma combined with hypothermia. After an additional loading 
dose of 5mg/kg the dosage of thiopental was adapted to a burst suppression pattern 
in continuous EEG-monitoring. Postoperative CT scan showed multiple infarctions on 
both hemispheres (fig. 5). A decompressive craniectomy was performed. The patient 
died with ischemic brain edema induced by untreatable ICP elevations and the 





A 36 years old female patient with fatal perioperative ischemic complication on the 
not operated side is reported. This female patient, with multiple postoperative 
ischemic infarctions, showed a metabolic acidosis, twice treated with 50ml Na-
bicarbonate 8.4%, which persisted over 30 hours postoperatively. There was only a 
two hours period of mild hyperventilation during the operation, no episode of 
hypotension, no signs of hypovolemia or hemoconcentration occurred and no volatile 
anesthetics were used. Although the precise mechanisms leading to multiple cerebral 
infarctions remain speculative, occurring metabolic acidosis may be an event we 
have to pay attention in the perioperative treatment of patients with Moyamoya 
disease.   
Metabolic changes after H215O-PET with acetazolamide: Ischemic events induced 
by acetazolamide challenge are described in single patients (10, 11). Lee et al. report 





a stenosis of the midportion of the basilar artery, developing reversible pontine 
ischemia immediately after acetazolamide challenge has been described (11). In a 
series of 9 patients with occlusion of the internal carotid artery, Vorstrup and 
coauthors found 2 patients after acetazolamide test showing a paradoxical decrease 
in focal CBF, which has been designated the steal phenomenon (12). Acetazolamide, 
a carbonic anhydrase inhibitor, is known as a diuretic agent and causal agent in 
metabolic acidosis (13). Acetazolamide is widely used for the treatment of glaucoma. 
Severe metabolic acidosis, rarely reported, occurs predominantly among elderly 
people, in patients with renal failure, diabetic type IV renal tubular acidosis and 
during concomitant use of other nephrotoxic drugs (14 – 18). Brechue et al. reported 
after application of clinical doses of acetazolamide a reduction in body fluid 
compartments leading to a moderate isotonic hypovolemia (13). Hematocrit 
increased significantly and significant loss of plasma water was documented. 
Furthermore the authors found metabolic acidosis with a significant decrease in 
venous pH and plasma HCO3--. Acetazolamide changes the functional status of the 
carbonic anhydrase of the central nervous system (19,20). Javaheri et al. described 
that intravenous administration of 50mg/kg to 100mg/kg acetazolamide results in a 
considerable drop of the carbonic anhydrase concentration in the CSF (cerebrospinal 
fluid) in isocapnic metabolic acidosis (20). Carbonic anhydrase seems to be the 
major factor in maintaining CSF HCO3-- level in isocapnic metabolic acidosis when 
HCO3-- diffuses from CSF to blood (19,20). Neither HCO3-- nor the arterial PCO2 may 
influence the vascular tone per se, but the changes in perivascular pH due to 
changes in CSF HCO3-- concentration or arterial PCO2 may induce cerebrovascular 
constriction or dilatation (21). In vitro low pH in CSF relaxes cerebral vascular muscle 





varying HCO3-- concentration had no effect until the pH was allowed to change (22). 
Britton et al. demonstrated an inverse linear relationship between the CSF pH and 
total CBF (cerebral blood flow) (23). CSF acidity was changed by altered HCO3-- 
concentration while arterial PCO2 was kept constant. It could be demonstrated that 
both total and regional CBF values depend directly on CSF acidity. Regli et al. 
investigated the effects of acetazolamide on cerebral infarction after unilateral 
experimental occlusion of the middle cerebral artery in adult cats (24). Neurological 
deficits were more severe and the ischemic infarctions were more extended in 
animals given acetazolamide compared to control animals. The authors conclude 
that the acetazolamide induced decrease of pH in nonischemic brain tissue may be 
harmful for ischemic areas because vasodilatation in nonischemic brain may steal 
blood away from the area supplied by the compromised vessel.  
Other perioperative risk factors: Sumikawa et al. reported postoperative 
complications after anaesthetizing four patients with Moyamoya disease for surgical 
revascularization (5). They suggested that hypocapnia might be the main cause of 
neurological deficits after surgical treatment. The authors suppose that hypocapnia 
might steal blood from the area supplied by the compromised vessels. Iwama et al. 
retrospectively analyzed 21 patients with childhood Moyamoya disease who 
experienced ischemic complications not directly related to the surgery but during the 
perioperative period (4). The authors found that frequent occurrence of TIAs as an 
indicator of the instability of cerebral hemodynamics is a significant risk factor for 
perioperative ischemic complications. Multifactorial analysis showed that hypotension 
and hypocapnia did not independently affect the occurrence of complications, 
probably because they were rapidly treated and their duration was controlled. On the 





perioperative ischemic events. Another perioperative risk factor may be the use of 
volatile anesthetics such as isoflurane because of their strong cerebral vasodilatative 
effects (25,26). Global hyperemia due to cerebrovascular dilatation may cause 
intracerebral steal in compromised areas (26).  
Systematic evaluation of charts and perioperative blood gas analysis of Moyamoya 
patients: The charts and imaging studies of 14 patients with Moyamoya disease or 
syndrome who underwent 26 EC-IC bypass surgery sessions between November 
1997 and February 2001 at the Department of Neurosurgery, University Hospital 
Zurich, were reviewed. Patient characteristics are given in table 1. The clinical 
records were studied with special reference to intra- and postoperative mean arterial 
blood pressure, to blood gas data, the occurrence of postoperative ischemic 
complications and to the time between H215O-PET examination and the operation. All 
patients underwent H215O-PET examination using acetazolamide before surgery. For 
the standard H215O-PET scanning, 1g of acetazolamide was injected intravenously in 
adult patients and 0,1 to 0,5 g in pediatric patients as a bolus over 2 min. Before and 
during the operation hypovolemia was carefully avoided. Total intravenous 
anesthesia using propofol and fentanyl or remifentanyl was performed. In all patients 
an arterial catheter was placed to measure arterial pressure continuously and a 
central venous line to control central venous pressure (CVP). To avoid hyper- or 
hypoventilation the end-tidal CO2 concentration was measured continuously. Blood 
gas analysis (Ciba Corning system) were performed immediately at the beginning of 
the operation, after the induction of anesthesia and as soon as possible after 
postoperative arrival of the patient in the neurosurgical intensive care unit.  
Concerniong the surgical technique, classical STA (superficial temporal artery) - 





After bypass surgery the patients were supervised and treated in the neurosurgical 
intensive care unit for 24 hours. Non surgical technique related postoperative 
complications were described as the patient developing transient or permanent 
neurological deficits or generalized seizures. If deficits or seizures occurred 
intracerebral hemorrhage was excluded with CT scan examination and EC-IC bypass 
was documented to be patent with extra-/transcranial Doppler sonography. In 14 
patients with Moyamoya disease with 26 EC-IC bypass operations one fatal ischemic 
complication on the not operated side occurred (table 1). Perioperative data were 
available from 26 EC-IC bypass sessions in 14 Moyamoya patients. Patient 
characteristics were expressed as mean (±SD). The Mann Whitney U-test was used 
to compare pH, HCO3-- and PaCO2 between different cases. Statistical significance 
was assumed at a p-value <0.05.Mean time from H215O-PET examination to the 
operation in all patients was 665 hours. The values of blood gas analysis were 
compared between two groups (table 2).  Group one included nine cases in which 
EC-IC bypass surgery was performed within 48 hours after the H215O-PET 
examination with acetazolamide. Group two comprised the 17 cases where the 
operation was performed more than 48 hours after the H215O-PET examination with 
acetazolamide. In group one seven from nine patients (77.8%) showed intraoperative 
pH values below 7.35 corresponding with metabolic acidosis, whereas only three 
from 17 patients (17.6%) in group two had pH values below 7.35. In group one 
intraoperative pHmean was 7.328, which was significantly lower than in group two  with 
pHmean 7.393 (p<0.0001). Intraoperative HCO3-- was significantly lower in group one 
compared to group two (17.6 compared to 20.1 mmol/l; p=0.0165). Base excess (BE) 
was lower in group one than in group two (--7.0 compared to --3.5; p=0.0165). The 





two groups. After the operation pHmean in all patients increased from 7.370 to 7.383. 
pHmean still tended to be lower in group one than in group two but without 
significance. HCO3--mean postoperatively was still significantly lower in group one 
compared to group two (18.1 compared to 20.5 umol/l; p=0.0132). Time interval 
between the H215O-PET examination with acetazolamide and the operation 
correlated with the pH values (Spearman r=0.52; p<0.001) and with the HCO3-- 
values (Spearman r=0.77; p<0.001). In patients operated within 48 hours after the 
H215O-PET with acetazolamide metabolic acidosis occurred significantly more often 
and more pronounced than in patients operated later than 48 hours after the 
examination. Six patients underwent bilateral surgical revascularization in two 
sessions with two different time intervals after the H215O-PET examination with 
acetazolamide challenge (within 48 hours and after 48 hours). Box plots with the 
values obtained from the same patients in the two sessions are given in figure 6. 
pHmean and HCO3-mean obtained during surgery within 48 hours after the H215O-PET 
were significantly lower than the corresponding values obtained during surgery later 
than 48 hours after the examination (7.313 compared to 7.388: p=0.0152; 17.3 
compared to 20.3 mmol/l; p=0.0299). PaCO2mean was not different in the two sessions 
(4.6 kPa in both sessions). 
Implications for perioperative treatment of patients with Moyamoya disease. H215O-
PET with acetazolamide loading test may lead to hypovolemia, systemic metabolic 
acidosis and acidosis in the CSF. CSF acidosis may cause a reactive dilatation of 
unimpaired vessels (23). This may result in a decrease of perfusion in chronic 
ischemic areas in which the vessels are already maximally dilated (26). 
Acetazolamide induced effects in CSF may last on even if the drug has essentially 





i.v. in dogs and found significant concentrations in the choroid plexus as a tissue 
enzyme site still after 6 days (27).  These acetazolamide induced disturbances might 
become clinically relevant if EC-IC bypass surgery is performed early after the H215O-
PET examination with acetazolamide. Additional perioperative factors such as 
hypocapnia, hypercapnia, hypotension, hypovolemia or volatile anesthetics may 
aggravate cerebral hemodynamic imbalance. To prevent perioperative ischemic 
complication efforts must be made to establish optimal perioperative conditions. 
However, H215O-PET or SPECT examinations using acetazolamide can demonstrate 
cerebral hemodynamic changes after surgery and have been considered to be 
indispensable for evaluating pre- and postsurgical cerebral hemodynamics (28,29). 
Patients after H215O-PET or SPECT examinations therefore have to be carefully 
observed concerning acidosis and volume state. On the basis of our cases, we 
recommend that a time interval of more than 48 hours should be kept between the 
H215O-PET or SPECT examination with acetazolamide challenge and surgery. The 
present illustrative case might not give evidence enough, that acidosis has the 
potential to induce cerebral ischemia. Nevertheless, occurring metabolic acidosis 
may be an event we have to pay attention in the perioperative treatment of patients 
with Moyamoya disease after the H215O-PET examination with acetazolamide. 
Furthermore, special care should be taken to avoid additional risk factors such as 
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Fig. 1. Preoperative MRI, axial T2-weighted image: Subacute infarction in the left 
frontal and temporo-parietal region. 
 
Fig. 2. Preoperative left internal carotid angiogramm: Arterial phase shows the typical 
Moyamoya pattern. Stenosis of the A1- and M1-segment with collateral 
lenticulostriatae arteries. A: AP view. B: Oblique view. 
 
Fig. 3. Preoperative right internal carotid angiogramm: Late arterial phase shows 
slightly stenosis of the C1-segment. A: AP view. B: Lateral view. 
 
Fig. 4. Preoperative PET examination with acetazolamide test. Top row: CBF at 
baseline. Reduced perfusion can be seen in the left parietal region. Middle row: CBF 
after acetazolamide loading. Bottom row: CBF reserve capacity. Reserve capacity is 
reduced except cerebellar, occipital, in the thalamus and striatum. Note the steal 
phenomenon in the right frontal region. 
 
Fig. 5. CT examination shows severe acute infarctions in the right MCA and ACA 
territory on both sides. Brain edema resulting in brain herniation. 
 
Fig.6. Patients who had surgeries with two different intervals. In six patients bilateral 
surgical revascularization was performed in two sessions with two different time 
intervals. Right box plots show median values, 25% and 75% percentiles and 





after the H215O-PET examination with acetazolamide. Left columns show the values 
obtained during surgery with a time interval of less than 48 hours after the H215O-PET 
examination with acetazolamide. 
 
Table 1. Patient characteristics in all patients and patient subgroups 
 
     
      All patients  Group 1 
 Group 2 
 
Number of patients    14    
Males     5       
Females    9       
Age mean (SD)    14.4 (10.4) 
Number of operations   26   9   17 
Unilateral EC-IC anastomosis 25   8   17 
 Bilateral EC-IC anastomosis 1   1   0 
Outcome 
       No postoperative deficits  25   8   17
  
Permanent postoperative  1*   1*   0 
neurological deficit    
 
 
Group 1: Cases with operation within 48 hours after H215O-PET+acetazolamide; Group 2: 
Cases with operation later than 48 hours after H215O-PET+acetazolamide; *Patient died 4 






Table 2. Values of blood gas analysis in all patients and patient subgroups 
 
     
     All patients  Group 1  Group 2
  
           
Number of operations  26   9   17 
 
Time between H2O-PET and 665.19   23.37   1005.03 
surgery (hours) +SD  + 770.24  + 12.21  + 686.10 
 
Intraoperative values  
    
 pHmean    7.370   7.328   7.393 
+SD    + 0.059  + 0.057  + 0.047 
           p < 0.0001 
 
HCO3--mean (umol/l)  19.2   17.6   20.1 
+SD    + 2.4   + 2.2   + 2.1 
          p = 0.0165 
 
BE    -- 4.7   -- 7.0   -- 3.5 
     + 3.2   + 3.3   + 2.4 
           p = 0.0165 
 
 PaCO2mean (kPa)  4.5   4.5   4.5 
 +SD    + 0.5   + 0.5   + 0.5 
            ns 
Postoperative values 
 
pHmean    7.383   7.362   7.395 
+SD    + 0.077  + 0.092  + 0.068 
           ns 
 
HCO3--mean (umol/l)  19.6   18.1   20.5 
+SD    + 2.5   + 2.3   + 2.2 
          p = 0.0132 
 
BE    -- 4.3   -- 5.7   -- 3.5 
     + 3.0   + 3.6   + 2.5 
            ns 
 
 PaCO2mean (kPa)  4.5   4.3   4.7 
 +SD    + 1.0   + 0.8   + 1.1 




Group 1: Cases with operation within 48 hours after H215O-PET+acetazolamide; Group 2: 
Cases with operation later than 48 hours after H215O-PET+acetazolamide; Intraoperative 
values: first values obtained by blood gas analysis at the beginning of surgery; Postoperative 
values: first values obtained by blood gas analysis immediately after the patient arrived in the 





statistical significant; ns = statistical not significant; Statistical significance was assumed at a 
p-value <0.05. 
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